Key facts
- It has raised $17.3M; the latest was Later Stage VC in Jun 2025.
- Notable investors include Puhua Capital, Ennovation Ventures, KGW Investment, Longmen Capital, Nanjing Jiangbei New Area Science and Technology Investment Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Zhongji Zhiyao
- ·The full record, as it builds
Funding rounds
No funding rounds for Zhongji Zhiyao are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zhongji Zhiyao
Developer of biological research reagents designed for use in cell and gene therapy applications. The company's platform focuses on the production of GMP-grade upstream reagents, including transfection agents, cytokines, and serum-free media, enabling biomedical research and therapeutic development markets to access standardized, high-purity materials that support reproducibility, regulatory compliance, and scalable manufacturing processes.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Website
- genmedicn.com/
- Ownership
- Privately Held (backing)
Zhongji Zhiyao doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zhongji Zhiyao shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zhongji Zhiyao in its N-PORT filings yet. We sweep new filings monthly.